Histone deacetylase inhibitors in the generation of the anti-tumour immune response

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 33-38

  Leggatt, Graham R ^a   Gabrielli, Brian ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

chemotherapy; HDAC inhibitor; immunotherapy; tumour

Indexed keywords

ALPHA INTERFERON; CD40 ANTIGEN; DNA VACCINE; ENTINOSTAT; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; LYSINE; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT INTERLEUKIN 2; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CD8+ T LYMPHOCYTE; CELL DEATH; CELL FUNCTION; CHROMATIN STRUCTURE; COLON CANCER; CYTOSTASIS; CYTOTOXICITY; DNA IMMUNIZATION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LONG TERM CARE; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; TH2 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR RECURRENCE; UPREGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84855432518     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.94     Document Type: Review

References (83)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
2. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009; 69: 1911-1934.
3. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
4. Duvic M, Vu J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111-1120. (Pubitemid 47074165)
5. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Geneexpression profilingof multiple histonedeacetylase(HDAC) inhibitors: defininga common geneset produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151-163.
6. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. Identifica-tion and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697-3702. (Pubitemid 40354674)
7. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversibleacetylation. Trends Cell Biol. 2005; 15: 565-567. (Pubitemid 41619418)
8. Subramanian C,Opipari Jr AW, Bian X,Castle VP, Kwok RP. Ku70acetylationmediates neuroblastoma cell death induced byhistonedeacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 4842-4847. (Pubitemid 40471541)
9. Bernhard D, Skvortsov S, Tinhofer I, Hubl H, Greil R, Csordas A et al. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ 2001; 8: 1014-1021. (Pubitemid 32998273)
10. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. Novel mechanismsof apoptosis induced by histonedeacetylase inhibitors. Cancer Res 2003; 63: 4460-4471. (Pubitemid 36951018)
11. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-6701. (Pubitemid 39280001)
12. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6796.
13. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001; 60: 828-837. (Pubitemid 32900266)
14. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000; 11: 2069-2083. (Pubitemid 30408065)
15. Stevens FE, Beamish H, Warrener R, Gabrielli B. Histonedeacetylase inhibitors induce mitoticslippage. Oncogene 2008; 27: 1345-1354.
16. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. Faseb J 2003; 17: 1550-1552.
17. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 2004; 23: 1342-1353. (Pubitemid 38406830)
18. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetyla-tion, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002; 1: 937-941.
19. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther. 2005; 4: 197-206. (Pubitemid 41351319)
20. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon gamma-dependent tumor surveillancesystem in immunocompetentmice. Proc Natl Acad Sci USA 1998; 95: 7556-7561. (Pubitemid 28293291)
21. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgammaand lymphocytes prevent primarytumour development and shapetumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
22. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunitytocancer. Annu Rev Immunol 2011; 29: 235-271.
23. Quatan N, Spicer J, Plunkett T, Pandha H. Cellular immunotherapyforcancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I. Clin Oncol (R Coll Radiol) 2004; 16: 356-365. (Pubitemid 38967257)
24. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006; 18: 201-205. (Pubitemid 43327303)
25. Kaufmann SH, Vaux DL. Alterations in the apoptotic machineryand their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414-7430. (Pubitemid 37487167)
26. Melcher A, Gough M, Todryk S, Vile R. Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med 1999; 77: 824-833. (Pubitemid 30062563)
27. Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E et al. Macrophages orchestrate the immune response to tumor cell death. Cancer Res 2001; 61: 7240-7247. (Pubitemid 32946521)
28. Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004; 4: 223-231. (Pubitemid 38339088)
29. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8T cells. J Immunol 2003; 170: 4905-4913. (Pubitemid 36554719)
30. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003; 103: 205-211. (Pubitemid 35461512)
31. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissuecells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-434.
32. Buttiglieri S, Galetto A, Forno S, De Andrea M, Matera L. Influence of drug-induced apoptotic death on processingand presentation oftumorantigens bydendritic cells. Int JCancer 2003; 106: 516-520. (Pubitemid 36966207)
33. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cellstriggers inflammation. Nature 2002; 418: 191-195. (Pubitemid 34773774)
34. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-830. (Pubitemid 39199174)
35. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobilitygroupbox-1 protein. Immunity 2008; 29: 21-32. (Pubitemid 351952462)
36. Ferguson TA, Choi J, Green DR. Armed response: how dying cells influence T-cell functions. Immunol Rev 2011; 241: 77-88.
37. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Embo J 2003; 22: 5551-5560. (Pubitemid 37279964)
38. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 2010; 285: 39888-39897.
39. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother 2004; 53: 748-754. (Pubitemid 38962069)
40. Khan AN, Magner WJ, Tomasi TB. An epigeneticvaccine model active in the prevention and treatment of melanoma. J Transl Med 2007; 5: 64.
41. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langen-kamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLAclass I specificities. Blood 2008; 111: 1428-1436. (Pubitemid 351213430)
42. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-6329. (Pubitemid 40994418)
43. Terbach N, Williams RS. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans 2009; 37: 1126-1132.
44. Bressan A, Bigioni M, Bellarosa D, Nardelli F, Irrissuto C, Maggi CA et al. Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA. Oncol Rep 2010; 24: 1249-1255.
45. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136-11145. (Pubitemid 41713385)
46. Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillanceofcancer. Oncogene 2009; 28: 2370-2382.
47. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96: 3847-3856.
48. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C et al. Activation of MHC class II I, and CD40 gene expression by histone deacetylase inhibitors. JImmunol 2000; 165: 7017-7024. (Pubitemid 32001174)
49. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008; 57: 647-654.
50. Chou SD, Khan AN, Magner WJ,Tomasi TB. Histoneacetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 2005; 17: 1483-1494. (Pubitemid 41631324)
51. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 byhistonemodifications. Cancer Res 2006; 66: 10770-10777. (Pubitemid 44876972)
52. Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 2011; 31: 233-263.
53. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
54. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010; 10: 369-373.
55. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory Tcells. Nat Med 2007; 13: 1299-1307. (Pubitemid 350073591)
56. Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136: 348-363
57. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31: 2066-2078.
58. Liu Z, Zhang C, Sun J. Deacetylase inhibitor trichostatin A down-regulates Foxp3 expressionand reduces CD4+CD25+ regulatory Tcells. Biochem Biophys Res Commun 2010; 400: 409-412.
59. Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 2000; 96: 1490-1495. (Pubitemid 30658481)
60. Matsuoka H, Fujimura T, Hayashi M, Matsuda K, Ishii Y, Aramori I et al. Disruption of HDAC4/N-Co R complex by histone deacetylase inhibitors leads to inhibition of IL-2 geneexpression. Biochem Pharmacol 2007; 74: 465-476. (Pubitemid 46963237)
61. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 2011; 186: 3986-3996.
62. Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br JPharmacol 2011; 162: 1590-1602.
63. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M et al. The histone deacetylase HDAC11 regulates theexpression of interleukin 10and immunetolerance. Nat Immunol 2009; 10: 92-100.
64. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000. (Pubitemid 34240574)
65. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler Tet al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
66. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009; 182: 5899-5903.
67. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC func-tions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118: 2562-2573. (Pubitemid 351949783)
68. Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011; 25: 161-168.
69. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-1130. (Pubitemid 46220659)
70. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007; 70: 1-11. (Pubitemid 46890289)
71. Simson L, El lyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS et al. Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance. JImmunol 2007; 178: 4222-4229. (Pubitemid 46492372)
72. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ Tcell responses. BMC Cancer 2003; 3: 30.
73. Jones K, Nourse J, Corbett G, Gandhi MK. Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. Int JLab Hematol 2010; 32: e169-e174.
74. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7: 263-283.
75. Vanniasinkam T, Ertl H, Tang Q. Trichostatin-Aenhancesadaptive immuneresponsesto DNA vaccination. J Clin Virol 2006; 36: 292-297.
76. Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF et al. An HDAC inhibitor enhances theantitumor activity of a CMVpromoter-driven DNA vaccine. Cancer Gene Ther 2010; 17: 203-211.
77. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007; 13: 4538-4546. (Pubitemid 47219724)
78. Juengel E, Bhasin M, Libermann T, Barth S, Michaelis M, Cinatl Jr J et al. Alterationsof the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha. World J Urol 2010 (e-pub ahead of print July 17; doi:10.1007/s00345-010-0582-y).
79. Fujisawa T, Joshi BH, Puri RK. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J Transl Med 2011; 9: 37.
80. Norian LA, Kucaba TA, Earel JK, Knutson T, Vanoosten RL, Griffith TS. Synergistic Inductionof Apoptosis in Primary B-CLLCellsafter Treatmentwith Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibi-tors. J Oncol 2009; 2009: 408038.
81. Martin BP, Frew AJ, Bots M, Fox S, Long F, Takeda K et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int J Cancer 2011; 128: 2735-2747.
82. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008; 105: 11317-11322.
83. Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulat-ing antibodies. Proc Natl Acad Sci USA 2011; 108: 4141-4146.